Abstract: Abnormal angiogenesis is an important pathological characteristic of recurrent respiratory papillomatosis (RRP). Bevacizumab, by blocking the vascular endothelial growth factor (VEGF)/vascular endothelial growth factor receptor (VEGFR) signaling pathway, promotes the normalization of aberrant angiogenesis and vascular permeability in RRP lesions. This action results in a reduction of lesion burden, prolonging the interval between surgical interventions, and improving airway⁃related symptoms. Multiple studies have confirmed the therapeutic efficacy of Bevacizumab in the treatment of RRP, with acceptable short⁃term adverse events. This consensus was developed by the writing group based on published clinical evidence on Bevacizumab in RRP and clinical practice. Through multiple rounds of expert deliberation, a unified set of recommendation was formulated to guide the rational and standardized application of Bevacizumab in relevant clinical departments in China, thereby improving the standardization of RRP diagnosis and treatment.

Key words: Recurrent respiratory papillomatosis, Bevacizumab, Antiangiogenic drugs, Expert consensus